cancer de mama 3n
TRANSCRIPT
Dr. Adrián Agustín Nervo
Cancer de Mama Triple NegativoHeterogeneidad TumoralRol de Platinos e Inhibidores PARP
Cancer de Mama Triple Negativo
5
Triple Negativo
PertuzumabTDM1
HerceptinLapatinibPertuzumabTDM1
TamoxifenoIAFulvestrantInhibidores mTorInhibidores cDK
No target disponible
90% DE LOS BRCA 1 MUTADOS
80-90% SON SIMIL – BASALES
10-15% DE LOS TN SON BRCA1 MUTADOS
Triple Negativo
Triple Negativo
Característica Clínicas del 3N
• No asociación consistente con status nodal o estadio y evolución
• Patron de Recaída– Alto riesgo– ILE corto– Sitio diferente de los
luminales:– SNC 30-45%
0.35
0.30
0.25
0.15
0.10
0.05
0
HR 0.20
Other (290 of 1421)Triple negative (61 of 180)
n Bone, %
Soft Tissue, % Viscera, %
TNBC 79 13 13 74
ER+ 123 39 7 54
HER2+ 78 7 12 81
Respuesta a la QT Neoadyuvante
• TNBC often responsive to conventional NAC with good outcome similar to other subtypes
• < pCR = poorer outcome1.0
0.9
0.8
0.7
0.6
0.5
0.41
Yrs After Surgery2 3 4 5 6 7
Prob
abili
ty o
f Bei
ng A
live
pCR/non-TNBCpCR/TNBCRD/non-TNBCRD/TNBC
98%94%
88%
68%
P = .24
P = .0001
21 publically available gene expression data sets587 TNBC
San Antonio Breast Cancer Symposium, December 9-13, 2014
3N
Basal-like 1 and 2
Mesenchymal-like
Luminal-AR
Immunomodulatory
Vanderbilt: subtipos de 3N- TNBCtype
Lehman et al JCI 2012
Mesenchymal Stem-like
San Antonio Breast Cancer Symposium, December 9-13, 2014
Subtipos Moleculares de Cáncer de Mama
3N
Posible origen de los subtipos 3N
Lim et al Nat Med 2009
Luminal AR
Mesenchymal stem-like
Basal-like+- mesencyhmal features
San Antonio Breast Cancer Symposium, December 9-13, 2014
Dos subtipos mayores de 3N
Masuda et al CCR 2013
Subtypes split by intrinsic subtype by PAM50
San Antonio Breast Cancer Symposium, December 9-13, 2014
Basal-like 1 and 2
Mesenchymal-like
Luminal-AR
Immunomodulatory
Vanderbilt: subtipos de 3N
Lehman et al JCI 2012
Mesenchymal Stem-like
San Antonio Breast Cancer Symposium, December 9-13, 2014
Basal-like
Luminal
Significancia Clínica de los subtipos 3N
Basal-like TNBCLuminal AR
~80% TNBC10-15% TNBC
San Antonio Breast Cancer Symposium, December 9-13, 2014
High expression hormonal driven pathways
Express androgen receptor
Sensitive in vitro to Bicalutamide
Líneas celulares Luminal AR
San Antonio Breast Cancer Symposium, December 9-13, 2014 Lehman et al JCI 2012
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor Negative Metastatic Breast Cancer
(TBCRC 011)
ER/PR negative (<=10% b IHC) but AR positive (>10% IHC)
Bicalutamide 150mg qd
Screened 424 patients 12% AR positive – 28 treated on study
0% Response rate
19% (5/26) stable disease >6 months
Benefit possible in strongly AR positive
Trials with Abiraterone and Enzalutamide ongoing
Gucalp et al CCR 2013San Antonio Breast Cancer Symposium, December 9-13, 2014
Masuda et al CCR 2013
Significancia Clinica de la expresión genética de los subtipos
35% LAR intermediate grade
Chemotherapy response – possibly lower pCR in LAR although including RCB-1 no clear difference
San Antonio Breast Cancer Symposium, December 9-13, 2014
Significancia Clínica de los subtipos 3N
Basal-like TNBCLuminal AR Mesenchymal Stem-like
~80% TNBC10-15% TNBC5-10% TNBC
San Antonio Breast Cancer Symposium, December 9-13, 2014
Ca Mama 3N-Mesenchymal stem-like
• Superposición con claudin-low y cáncer de mama metaplásico
• Enriquecido por expresión stem cell-like
• Menor tasa de proliferación que los basal-like
• Frecuente infiltrado inmune
• Niveles intermedios de mutación PIK3CA
San Antonio Breast Cancer Symposium, December 9-13, 2014
Basal-like 1 and 2
Mesenchymal-like
Luminal AR
Immunomodulatory
Vanderbilt: subtipos de 3N
Lehman et al JCI 2012
Mesenchymal Stem-like
San Antonio Breast Cancer Symposium, December 9-13, 2014
Tumour infiltrating lymphocyctes in breast cancer
Adams et al JCO 2014
3N Predminio Linfocitario
Stromal
Intra-tumoural
San Antonio Breast Cancer Symposium, December 9-13, 2014
Tumour infiltrating lymphocyctes in breast cancer
Loi et al JCO 2013
ALL ER pos
TNBCHE
R23N Predominio Linfocitario
Analysis of BIG 02-98 AC-CMF +- docetaxel
pre-trastuzumabSan Antonio Breast Cancer Symposium, December 9-13, 2014
Adams et al JCO 2014
Intra-tumoural TILs
Stromal TILs
Tumour infiltrating lymphocyctes in breast cancer
3N Predominio Linfocitario
San Antonio Breast Cancer Symposium, December 9-13, 2014
Significancia clínica de los subtipos 3N
Basal-like TNBCLuminal AR Mesenchymal Stem-like
~80% TNBC10-15% TNBC5-10% TNBC
Lymphocyte predominant Lymphocyte depleted
San Antonio Breast Cancer Symposium, December 9-13, 2014
Basal-like 1 DNA repair activated
Mesenchymal-like
Luminal AR
Immunomodulatory
Vanderbilt: subtypos de 3N
Lehman et al JCI 2012
Mesenchymal Stem-like
Basal-like 2 Growth factor receptor
San Antonio Breast Cancer Symposium, December 9-13, 2014
Y saliendo de las tinieblas, vamos a algo más terrenal….o no
Targeting the positives in TNBC Platinums, PARPS and novel approaches to
high risk disease
Andrew TuttDirector
Breakthrough Breast Cancer Research CentreLondon
BRCA1 BRCA2 Mutation associated
Alexandrov et al Nature 2013
Stable genome- low instability
Unstable genome- high instability
TNBCs have highly variable Chromosome structural instability
Triple Negativo: Inestabilidad Genómicaalta heterogeneidad tumoral
pocas mutaciones pasibles de targets
BRCA1 está mutado en ≈15% de pacientes 3N
BRCA1/2 y mecanismos de reparación del ADN
Single strand breaks• Nucleotide excision repair
• Base excision repair• PARP1
Replication lesions• Base excision repair
– PARP1
DNA adducts/base damage • Alkyltransferases
• Nucleotide excision repair
• Base excision repair– PARP1
DNA DAMAGE
Cell death
Environmental factors(UV, radiation, chemicals)
Normal physiology(DNA replication, ROS)
MAJOR DNA REPAIRPATHWAYS
Chemotherapy(alkylating agents, antimetabolites)Radiotherapy
Helleday T, et al. Nat Rev Cancer. 2008;8:193-204. O’Shaughnessy J, et al. ASCO 2009. Abstract 3. Reproduced with permission.
Double strand breaks Nonhomologous end-joining Homologous recombination
– BRCA1/BRCA2
Fanconi anemia pathway Endonuclease-mediated repair
PlatinoUna Larga historia en Cáncer de Mama……
1988 JCO
Platino e Inhibidores de la PARP
BRCA-1BRCA-2
1. Platinum chemotherapyInflicts DNA damage via adducts and DNA crosslinking
2. PARP1upregulationsBase-excision repair of DNA damage
3. Inhibition of PARP1Disables DNA base-excision repair
Cell Survival Cell Death
PARP inhibitor
Pt
Pt
Pt
Pt
Pt
PARP1
PARP1
PARP1
Activo en TNBC BRCA 1 BRCA1 sensibles a agentes
que producen cross-link en el DNA
Platino en 3N metastásicos
TNT Trial-Abst S3-01
RECIST ORR
TTPPFS
ORR 2nd lineToxicity
OS
376 patients
First Line Advanced TNBC or BRCA1/BRCA2 Breast Cancer
Central ER / PR / HER2 Basal PhenotypesGermline BRCA1/2
genotype53BP loss
HR Genome ScarSomatic BRCA1/2
BRCA1 methylationWhole Exome NGS
RNA Seq
Recurrent Disease BXGenome Scars
Reversion MutationsWhole Exome NGS
RNA Seq
Correlative BiologyProgram
TNT - Trial
TNT-Trial Abst S3-01
Platino en 3N metastásico
• Pocos Trials TN específicos ->mayormente subsets• Generalmenteplatinosevaluadosencombinación• Variasdefiniciones de“triple-negativo”• BRCA1/2 mutacionesraramentecaracterizadas
Se nececitanmásestudiosrandomizadoscomparandoplatinos a QT standard of care en 1 y 2línea de tratamientoenenfermedadmetastásica. TNT??
San Antonio Breast Cancer Symposium December 9-13, 2014
BRCA1 Mutation
Carriers with Tumors >2cm
Clinical and Pathological Response
Platino en Neoadyuvancia en BRCA1 Mutatados
.
CISPLATIN 75mg/m2
q 3wks IV x 12 wks
•N = 25•median age: 46 •28% with clinically positive lymph nodes•22 pts completed 4 cycles of Cisplatin
Pathological Response 72%
Gronwald et al ASCO 2009
Platino en Neoadyuvancia
Platino en Neoadyuvancia
Alta pCR con antraciclinas y taxanos en BRCA1/2 mutados
• BRCA1 mutation pCR 46% vs 22% non-carriers
• Is the effect specific to platinum vs standard of care?
• Requires planned subgroup analyses in randomised trials
Arun B et al -- J Clin Oncol 29:3739-3746
Platino no standard en neo/adyuvanciaSeguimos con nuestro combo
AC x4 – Paclitaxel w
Lig3XRCC1
PolßPNK
PARP
• Rol clave en la reparación del ADN (SSB)• Utiliza la vía de excisión de bases como reparación• Se une directamente al sitio de ADN dañado• Una vez activada, utiliza a NAD como substrato generando múltiples
cadenas de poly(ADP-ribose) • Recluta otras enzimas reparadoras de ADN
Inhibidores PARP
BRCA-1BRCA-21. Platinum chemotherapy
Inflicts DNA damage via adducts and DNA crosslinking
2. PARP1upregulationsBase-excision repair of DNA damage
3. Inhibition of PARP1Disables DNA base-excision repair
Cell Survival Cell Death
PARP inhibitor
Pt
Pt
Pt
Pt
Pt
PARP1
PARP1
PARP1
• Las células con BRCA-1 and BRCA-2 deficiente son marcadamente sensibles a inhibidores PARP
• En presencia de un inhibidor PARP , tienen una marcado déficit en la capacidad de repararse y esto conduce a la apoptosis
Inhibidores PARP en gBRCA m
400 mg td 100 mg td
Estudios en marcha……
R
Potent PARP inhibitor at MTD as
continuous exposure
Physician Choice within SOC options
Capecitabineor
Vinorelbineor
Eribulinor
Gemcitabine
gBRCA1 / BRCA2 Carriers
Advanced anthracycline taxane
resistant breast cancer
Primary endpoint
PFS
Niraparib – BRAVO Trial
BMN 673 – EMBRACA - NCT01945775
OLYMPIAD – Olaparib - NCT02000622
Selective tumor cell killingIncreased
normal tissue toxicity
predicted
Degree of PARP trapping of
inhibitor may be relevant
Combinando QT target con inhibición PARP
BRCA status and HRD Score examined in PrECOG 0105
Every 21 days x 6 cyclesn = 80
Definitive SurgeryAssess
Pathologic Response
Carboplatin AUC 2 D 1, 8
Gemcitabine 1000 mg/m2 D 1, 8
Iniparib 5.6 mg/kg D 1, 4, 8, 11
Newly Diagnosed
Stage I-IIIA (T 1cm by
MRI)
Triple-negative (ER/PR ≤ 5%)
or
BRCA1/2 mutation
Primary Endpoint: Pathologic complete response (pCR) [no invasive disease in breast + axilla]
Secondary Endpoints: Radiographic response by MRI Breast conservation eligibility
SafetyCorrelation of gene expression profiles & gene copy number
with responseTelli et al ASCO 2013
Alta Respuesta Patológica asociada con mutación BRCA1/2
Pathologic Response (n=80)All patients
*******
n = 80
BRCA 1/2 wild-type
n = 61
BRCA 1/2 mutant
n = 19
TN & BRCA 1/2 mutant
n = 16
pCR [RCB 0]; n (%) 29 (36%) 20 (33%) 9* (47%) 9* (56%)
90% CI 27–46 23–44 27-68 33-77
RCB 0/1; n (%) 45 (56%) 31 (51%) 14 (74%) 12 (75%)
90% CI 46-66 40-62 52-89 52-91
* One BRCA1 carrier had bilateral TNBC & achieved pCR in both breasts
Can veliparib sensitized chemotherapy improve on a platinum directed chemotherapy approach?
NCT01506609
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC): Hoosier Cancer
Research Network BRE09-146 Abstract 1019
Sujaata Dwadasi, Yan Tong, Tom Walsh, Michael A. Danso, Cynthia X. Ma, Paula Silverman, Mary-Claire King, Susan M. Perkins, Sunil S. Badve, Kathy Miller
Presented by: Steven Isakoff - Discussant
Randomize
CisplatinX 4 cycle
Cisplatin +Rucaparib30mg IVx3dX 4 cycle
Rucaparib100mg PO q wkX 24 weeks
• Eligibility
– TNBC (or BRCA+)– Residual disease (RCB
2/3, M-P 0-2, node +)– No prior cisplatin (carbo
allowed)
– 128 patients– 65 cisplatin– 63 cis/rucaparib
Median RCB 2.6 v 2.7
1 Year DFSC 83% v C/R 83%
22/128 patients BRCA mutation
DFS C 85% v C/R 100%
Randomise 1:1Double blindN=1320
IDFS
Distant D
FS; O
S
Post neoadjuvant gBRCA TNBC,
Non-PathCR pts
Post adjuvant gBRCA TNBCT2 or N+
Olaparib 300 mg bd 12 month duration
Placebo 12 month duration
Restricted to Germline Mutation carriers
Mejorando la selección de PacientesA Post Neo-adjuvant Umbrella Trial Platform? PHOENIX
New DiagnosisPost-Rx residual disease
Neoadjuvant Rx
Relapse
Vs
No Relapse
Definitive Surgery
Second Adjuvant RxAllocated by
Genomic TriageBalko et al Cancer Discovery 2014
Conclusiones• Cáncer de mama TN tiene subpoblaciones con defectos en la
reparación del ADN: 10-15% BRCA1 mutados
• Defectos en la reparación HR puede generar sensibilidad a platinos o inhibidores PARP
• No data randomizada publicada sobre comparación de platinos vs standard of care en este grupo – TNT?
• Inhibidores PARP promisorios, pero…faltan resultados de estudios fase III
Conclusiones Triple Negativo
Antes de San Antonio 2014
= Después de San Antonio 2014